National Bank of Canada’s Pacific Biosciences PACB Stock Holding History

National Bank of Canada’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$259	Buy	+198	New	+$354	﹤0.01%	2780
2025 Q3	–	Sell	-1,084,578	Closed	-$1.34M	–	3128
2025 Q2	$1.34M	Buy	1,084,578 +712,978	+192%	+$823K	﹤0.01%	1228
2025 Q1	$438K	Buy	+371,600	New	+$570K	﹤0.01%	1347
2024 Q3	–	Sell	-2,000	Closed	-$2.38K	–	2968
2024 Q2	$2.38K	Hold	2,000	–	–	﹤0.01%	2399
2024 Q1	$3.54K	Hold	2,000	–	–	﹤0.01%	2376
2023 Q4	$19.2K	Hold	2,000	–	–	﹤0.01%	2028
2023 Q3	$16.1K	Hold	2,000	–	–	﹤0.01%	2084
2023 Q2	$26.6K	Hold	2,000	–	–	﹤0.01%	1941
2023 Q1	$23.1K	Hold	2,000	–	–	﹤0.01%	1925
2022 Q4	$16.3K	Sell	2,000 -4,000	-67%	-$34.5K	﹤0.01%	2058
2022 Q3	$35K	Buy	6,000 +3,400	+131%	+$19.5K	﹤0.01%	1820
2022 Q2	$12K	Buy	2,600 +1,960	+306%	+$11.9K	﹤0.01%	2218
2022 Q1	$6K	Hold	640	–	–	﹤0.01%	2515
2021 Q4	$13K	Buy	+640	New	+$15.4K	﹤0.01%	2279

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

National Bank of Canada's PACB Position: Q1 2026 in Review

National Bank of Canada opened a new position in Pacific Biosciences (PACB) in Q1 2026: 198 shares worth $259. The stake represents ﹤0.01% of the portfolio and ranks #2780 among its holdings. This is a return to the name: National Bank of Canada previously reported a position in PACB as recently as Q2 2025.

National Bank of Canada first reported a position in PACB in Q4 2021 and has held it in 14 quarters since. The position peaked at $1.34M in Q2 2025. 229 funds tracked by Wall St. Rank hold PACB as of Q1 2026.

National Bank of Canada held 198 shares of Pacific Biosciences worth $259 as of Q1 2026.
Pacific Biosciences was a new National Bank of Canada position in Q1 2026.
Pacific Biosciences made up ﹤0.01% of National Bank of Canada's portfolio in Q1 2026, its #2780 holding.
National Bank of Canada first reported a position in Pacific Biosciences in Q4 2021 and has held it in 14 quarters since.
National Bank of Canada's Pacific Biosciences position peaked at $1.34M in Q2 2025.
229 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2026.

Based on National Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.